Overview

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Phase:
PHASE3
Details
Lead Sponsor:
Vanda Pharmaceuticals
Treatments:
ponesimod